Post-traumatic Hypertrophic Olivary Degeneration with Palatal Myoclonus-A Case Report.

J Child NeurolMar 3, 2026 (epub)
Case ReportNeurology

Katherine Bailey, Jacob T Hanson, Suad Khalil

✦ AI-curated · Sources linked

Case in brief

A 7-year-old boy developed right-sided lip, palatal, and neck quivering and twitching two years after a motor vehicle accident. Several antiseizure medications did not help, but carbamazepine was followed by marked improvement. EEG captured the facial movements and audible palatal clicking without associated electrographic changes. Brain MRI findings were suggestive of hypertrophic olivary degeneration (HOD), consistent with injury involving the Guillain-Mollaret triangle and palatal myoclonus.

What made this case unusual

The authors’ literature review found no previous report of post-traumatic HOD in a person under 18; they identified one other reported post-traumatic case, in a 27-year-old man.

Diagnostic / clinical pearl

Palatal clicking and facial twitching may occur without an EEG correlate; MRI findings suggestive of HOD can support a structural explanation after trauma involving the Guillain-Mollaret triangle.

Source

PubMed · PMID 41773572

Published in J Child Neurol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.